Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC
Ana Oitabén1,2,3, Pablo Fonseca1,4, María J Villanueva1,5
1Translational Oncology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Sergas-Uvigo, 36204 Vigo, Spain.
Cancers
|June 10, 2022
Summary
Predicting immunotherapy response in Non-Small Cell Lung Cancer (NSCLC) is crucial. Liquid biopsy offers promising biomarkers, like ctDNA, to guide immune checkpoint inhibitor (ICI) treatment decisions.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Immune checkpoint inhibitors (ICIs) show efficacy in Non-Small Cell Lung Cancer (NSCLC), but patient response varies.
- Predictive biomarkers are needed to optimize ICI treatment strategies and improve patient outcomes.
- Liquid biopsy presents a minimally invasive approach for biomarker acquisition.
Purpose of the Study:
- To review current liquid biopsy-based biomarkers for predicting ICI response in NSCLC.
- To evaluate the advantages and disadvantages of various circulating biomarkers.
- To discuss the potential of liquid biopsy in clinical practice for NSCLC immunotherapy.
Main Methods:
- Literature review of studies on liquid biopsy biomarkers for ICI response in NSCLC.
- Analysis of circulating biomarkers including soluble PD-L1, non-coding RNA, immune cells, cytokines, and ctDNA.
- Evaluation of biomarker utility at baseline and during treatment monitoring.
Main Results:
- Various liquid biopsy biomarkers show potential for predicting ICI response in NSCLC.
- Challenges include technical heterogeneity, lack of consensus, and small study cohorts.
- Soluble PD-L1, ctDNA, and circulating RNAs are among the promising candidates.
Conclusions:
- Liquid biopsy holds significant promise for non-invasive prediction and monitoring of ICI treatment in NSCLC.
- Standardization of techniques and larger validation studies are essential for clinical implementation.
- Biomarkers from liquid biopsy can aid in personalized NSCLC treatment strategies.
